AI-generated analysis
Olyos's acquisition of NewScience is a strategic move aimed at expanding its presence in Iberian-speaking markets and solidifying its position as a leading player in Latin America’s health supplements market. With NewScience, Olyos gains access to Chile, where it holds about 20% market share, and enhances its distribution network across other Latin American countries. This acquisition not only leverages NewScience's established market presence but also integrates the target company under the Drasanvi brand, thereby accelerating regional expansion and consolidating Olyos’s footprint.
The transaction was valued at $24 million for a 100% stake in NewScience, reflecting an implied valuation multiple that aligns with Olyos’s growth aspirations. Given the deal's mechanics are not fully disclosed, the financing structure remains unclear; however, it is likely that Olyos utilized its €215 million continuation fund raised earlier to support this expansion phase.
This acquisition significantly shifts competitive dynamics in the health supplements market by consolidating Olyos’s leadership position in a rapidly growing segment. With NewScience on board, Olyos can leverage enhanced distribution and operational synergies to outpace local competitors and attract new customers through expanded product offerings under established brands like Drasanvi. Additionally, this strategic move positions Olyos to capture the high-growth potential of Latin American markets, which are expected to grow at a rate higher than 5-7% annually.
Looking ahead, key risks include potential integration challenges and cultural differences between French and Chilean operations. However, given Olyos’s proven track record of successful integrations and its robust commercial model, these risks appear manageable. The acquisition also opens new growth vectors by enabling Olyos to introduce Granions products in Latin America and capitalize on emerging trends in health supplements and dermo-cosmetics. Overall, this deal marks a critical milestone in Olyos’s international expansion strategy and underscores the group's ambition to become one of the top 10 European players in natural health and nutrition by 2030.
Olyos, a French healthcare company, completed the acquisition of NewScience from Chile for $24 million on December 31, 2025. The deal is aimed at strengthening Olyos' position in Iberian-speaking markets and solidifying its presence in the Latin American health supplements market.
| Acquirer | Olyos (France) |
|---|
| Target | NewScience (Chile) |
|---|
| Value | $24 million |
|---|
| Type | Acquisition |
|---|
| Closing Date | December 31, 2025 |
|---|
| Advisors | N/A (both buy-side and sell-side) |
|---|
Deal Mechanics
Olyos has not disclosed specific financial terms or key deal conditions for the acquisition of NewScience. The transaction, which was completed on December 31, 2025, reflects Olyos' strategy to accelerate its international growth and expand its portfolio in Iberian-speaking regions.
Strategic Rationale
Olyos aims to leverage NewScience's existing market presence and local expertise within the health supplements segment to enhance its competitive edge in Latin America. By integrating the two companies, Olyos expects to benefit from synergies and operational efficiencies that will support further expansion efforts.
Financial Context
The $24 million deal is part of a broader strategy by Olyos to increase its market share through strategic acquisitions in promising international markets. This acquisition follows other deals, including the takeover of Somatoline, and underscores Olyos' commitment to diversifying its portfolio while solidifying its leadership position.
Outlook
Olyos sees significant potential for growth in Latin America's health supplements market and believes that NewScience will play a crucial role in achieving these goals. The company is expected to continue pursuing similar acquisitions to further extend its reach across the region.